In a phase I clinical trial, melanoma patients were treated with six biweekly injections of DCs electroporated with mRNA encoding p53, survivin, and hTER and concurrent low-dose cyclophosphamide (2 × 50 mg/day biweekly).127. Here, TP53 is linked to melanoma.